VISTAGEN THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Increase (Decrease) in Contract with Customer, Liability of -$1.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$1.46M.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$447.00K, a 1414.71% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$284.00K.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$239.00K.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2026 was -$1.20M.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$412.00K, a 179.84% decline from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $516.00K, a 150.49% increase from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $206.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.46M 10-Q · filed 2026-08-14 | -$1.90M derived: sum of 2 quarters · filed 2026-08-14 | -$2.19M derived: sum of 3 quarters · filed 2026-08-14 | -$2.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | -$731.00K derived: sum of 2 quarters · filed 2026-06-15 | -$970.00K derived: sum of 3 quarters · filed 2026-06-15 | -$1.20M 10-K · filed 2026-06-15 |
| 2025-12-31 | -$284.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$523.00K derived: sum of 2 quarters · filed 2026-02-12 | -$748.00K 10-Q · filed 2026-02-12 | -$714.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$464.00K 10-Q · filed 2025-11-13 | -$430.00K derived: sum of 3 quarters · filed 2026-08-14 | -$646.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$225.00K 10-Q · filed 2026-08-14 | -$191.00K derived: sum of 2 quarters · filed 2026-08-14 | -$407.00K derived: sum of 3 quarters · filed 2026-08-14 | -$572.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | -$182.00K derived: sum of 2 quarters · filed 2026-06-15 | -$347.00K derived: sum of 3 quarters · filed 2026-06-15 | -$412.00K 10-K · filed 2026-06-15 |
| 2024-12-31 | -$216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$381.00K derived: sum of 2 quarters · filed 2026-02-12 | -$446.00K 10-Q · filed 2026-02-12 | -$625.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | -$165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$230.00K 10-Q · filed 2025-11-13 | -$409.00K derived: sum of 3 quarters · filed 2025-11-13 | $699.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$65.00K 10-Q · filed 2025-08-07 | -$244.00K derived: sum of 2 quarters · filed 2025-08-07 | $864.00K derived: sum of 3 quarters · filed 2025-08-07 | $612.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | $929.00K derived: sum of 2 quarters · filed 2025-06-17 | $677.00K derived: sum of 3 quarters · filed 2025-06-17 | $516.00K 10-K · filed 2025-06-17 |
| 2023-12-31 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $856.00K derived: sum of 2 quarters · filed 2025-02-13 | $695.00K 10-Q · filed 2025-02-13 | |
| 2023-09-30 | -$252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | -$413.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$161.00K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $206.00K 10-K · filed 2024-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |